No profile data available.
Enovis Corporation (ENOV) is a healthcare company in the bone and joint treatment equipment industry, based in Lewisville, United States, with about 7,802 full-time employees.
It reported revenue of $2.11 billion for fiscal year 2024, up 23.5% from fiscal year 2023, and net income of -$825.49 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $548.91 million, up 8.6% from a year before. Its largest business segment, Prevention and Recovery, brought in 51% of segment revenue in fiscal year 2025; United States was the largest region with 58%. Its market capitalization was $1.02 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Enovis reported $2.11 billion in revenue for fiscal year 2024, up 23.5% from $1.71 billion in fiscal year 2023. In Q3 2025 revenue was $548.91 million.
Prevention and Recovery, with $1.14 billion or 51% of segment revenue in fiscal year 2025. Next: Reconstructive (49%).
United States: 58% of revenue by region in fiscal year 2025, followed by International (42%).
$1.02 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (bone and joint treatment equipment) include Globus Medical, Inc. (GMED), Vericel Corporation (VCEL), Alphatec Holdings, Inc. (ATEC), Bioventus Inc. (BVS).